Literature DB >> 19779283

Differential diagnosis between radiation necrosis and glioma progression using sequential proton magnetic resonance spectroscopy and methionine positron emission tomography.

Takeshi Nakajima1, Toshihiro Kumabe, Masayuki Kanamori, Ryuta Saito, Manabu Tashiro, Mika Watanabe, Teiji Tominaga.   

Abstract

Differential diagnosis between radiation necrosis and tumor recurrence is important in the clinical management of glioma. Multi-modality imaging including proton magnetic resonance spectroscopy ((1)H-MRS) and positron emission tomography (PET) with L-[methyl-(11)C]methionine (MET) was evaluated. Eighteen patients underwent sequential (1)H-MRS and MET-PET. The expressions of metabolites including choline-containing compounds (Cho), creatine phosphate (Cre), and lactate (Lac) were calculated as the ratios of Cho to Cre (Cho/Cre) and Lac to Cho (Lac/Cho). The uptake of MET was determined as the ratio of the lesion to the contralateral reference region (L/R). The final diagnoses were determined by histological examination and/or follow-up MR imaging and clinical course. The Lac/Cho ratio was 0.63 +/- 0.25 (mean +/- standard deviation) in recurrence (7 cases) and 2.35 +/- 1.81 in necrosis (11 cases). The Lac/Cho ratio was significantly different between the two groups (p < 0.01). Consecutive investigation of (1)H-MRS revealed temporary elevation of Cho in 4 of 9 cases of necrosis, which could be identified as false positive findings for recurrence. Including those cases, MET-PET demonstrated significant difference in the L/R ratio between the two groups (2.18 +/- 0.42 vs. 1.49 +/- 0.35, p < 0.01). According to a 2 x 2 factorial table analysis, the borderline values of Lac/Cho and L/R to differentiate recurrence from necrosis were 1.05 and 2.00, respectively. (1)H-MRS is reliable and accessible for the differentiation of recurrence and necrosis, although the temporary elevation of Cho in the course of necrosis should be recognized. Additional MET-PET imaging can establish the diagnosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19779283     DOI: 10.2176/nmc.49.394

Source DB:  PubMed          Journal:  Neurol Med Chir (Tokyo)        ISSN: 0470-8105            Impact factor:   1.742


  25 in total

1.  The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma.

Authors:  Norbert Galldiks; Gabriele Stoffels; Christian Filss; Marion Rapp; Tobias Blau; Caroline Tscherpel; Garry Ceccon; Veronika Dunkl; Martin Weinzierl; Michael Stoffel; Michael Sabel; Gereon R Fink; Nadim J Shah; Karl-Josef Langen
Journal:  Neuro Oncol       Date:  2015-05-24       Impact factor: 12.300

Review 2.  Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategies.

Authors:  Nishant Verma; Matthew C Cowperthwaite; Mark G Burnett; Mia K Markey
Journal:  Neuro Oncol       Date:  2013-01-16       Impact factor: 12.300

Review 3.  Clinical Applications of Magnetic Resonance Spectroscopy in Brain Tumors: From Diagnosis to Treatment.

Authors:  Brent D Weinberg; Manohar Kuruva; Hyunsuk Shim; Mark E Mullins
Journal:  Radiol Clin North Am       Date:  2021-03-23       Impact factor: 2.303

4.  Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases.

Authors:  Timothy J Kaufmann; Marion Smits; Jerrold Boxerman; Raymond Huang; Daniel P Barboriak; Michael Weller; Caroline Chung; Christina Tsien; Paul D Brown; Lalitha Shankar; Evanthia Galanis; Elizabeth Gerstner; Martin J van den Bent; Terry C Burns; Ian F Parney; Gavin Dunn; Priscilla K Brastianos; Nancy U Lin; Patrick Y Wen; Benjamin M Ellingson
Journal:  Neuro Oncol       Date:  2020-06-09       Impact factor: 12.300

5.  Bevacizumab treatment leads to observable morphological and metabolic changes in brain radiation necrosis.

Authors:  Shingo Yonezawa; Kazuhiro Miwa; Jun Shinoda; Yuichi Nomura; Yoshitaka Asano; Noriyuki Nakayama; Naoyuki Ohe; Hirohito Yano; Toru Iwama
Journal:  J Neurooncol       Date:  2014-05-01       Impact factor: 4.130

Review 6.  Advances in Magnetic Resonance and Positron Emission Tomography Imaging: Assessing Response in the Treatment of Low-Grade Glioma.

Authors:  Michelle M Kim; Theodore S Lawrence; Yue Cao
Journal:  Semin Radiat Oncol       Date:  2015-02-21       Impact factor: 5.934

Review 7.  Discriminating radiation necrosis from tumor progression in gliomas: a systematic review what is the best imaging modality?

Authors:  Ashish H Shah; Brian Snelling; Amade Bregy; Payal R Patel; Danoushka Tememe; Rita Bhatia; Evelyn Sklar; Ricardo J Komotar
Journal:  J Neurooncol       Date:  2013-01-24       Impact factor: 4.130

Review 8.  Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis.

Authors:  T Nihashi; I J Dahabreh; T Terasawa
Journal:  AJNR Am J Neuroradiol       Date:  2012-11-01       Impact factor: 3.825

9.  Spectroscopy imaging in intraoperative MR suite: tissue characterization and optimization of tumor resection.

Authors:  Constantin Roder; Marco Skardelly; Kristofer Fingerle Ramina; Rudi Beschorner; Jürgen Honneger; Thomas Nägele; Marcos Soares Tatagiba; Ulrike Ernemann; Sotirios Bisdas
Journal:  Int J Comput Assist Radiol Surg       Date:  2013-10-20       Impact factor: 2.924

Review 10.  Advanced MR imaging of gliomas: an update.

Authors:  Hung-Wen Kao; Shih-Wei Chiang; Hsiao-Wen Chung; Fong Y Tsai; Cheng-Yu Chen
Journal:  Biomed Res Int       Date:  2013-06-04       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.